449 related articles for article (PubMed ID: 17644552)
1. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab.
Visvanathan S; Wagner C; Marini JC; Baker D; Gathany T; Han J; van der Heijde D; Braun J
Ann Rheum Dis; 2008 Apr; 67(4):511-7. PubMed ID: 17644552
[TBL] [Abstract][Full Text] [Related]
2. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system.
Braun J; Baraliakos X; Golder W; Brandt J; Rudwaleit M; Listing J; Bollow M; Sieper J; Van Der Heijde D
Arthritis Rheum; 2003 Apr; 48(4):1126-36. PubMed ID: 12687557
[TBL] [Abstract][Full Text] [Related]
3. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.
de Vries MK; van Eijk IC; van der Horst-Bruinsma IE; Peters MJ; Nurmohamed MT; Dijkmans BA; Hazenberg BP; Wolbink GJ
Arthritis Rheum; 2009 Nov; 61(11):1484-90. PubMed ID: 19877087
[TBL] [Abstract][Full Text] [Related]
4. Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximab.
Braun J; van der Heijde D; Doyle MK; Han C; Deodhar A; Inman R; de Vlam K; Burmester GR; Van den Bosch F; Xu S; Visvanathan S; Rahman MU
Arthritis Rheum; 2009 Aug; 61(8):1032-6. PubMed ID: 19644896
[TBL] [Abstract][Full Text] [Related]
5. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab.
Sieper J; Baraliakos X; Listing J; Brandt J; Haibel H; Rudwaleit M; Braun J
Rheumatology (Oxford); 2005 Dec; 44(12):1525-30. PubMed ID: 16091396
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
van der Heijde D; Dijkmans B; Geusens P; Sieper J; DeWoody K; Williamson P; Braun J;
Arthritis Rheum; 2005 Feb; 52(2):582-91. PubMed ID: 15692973
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab.
Brandt J; Haibel H; Cornely D; Golder W; Gonzalez J; Reddig J; Thriene W; Sieper J; Braun J
Arthritis Rheum; 2000 Jun; 43(6):1346-52. PubMed ID: 10857793
[TBL] [Abstract][Full Text] [Related]
8. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
Yang CH; Huang F; Deng XH; Zhang JL; Zhang LY; Guo JH; Liang DF; Wang LS; Zhang YM
Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(35):2451-4. PubMed ID: 17156669
[TBL] [Abstract][Full Text] [Related]
9. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis.
Rudwaleit M; Schwarzlose S; Hilgert ES; Listing J; Braun J; Sieper J
Ann Rheum Dis; 2008 Sep; 67(9):1276-81. PubMed ID: 18006539
[TBL] [Abstract][Full Text] [Related]
10. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.
Braun J; Baraliakos X; Brandt J; Listing J; Zink A; Alten R; Burmester G; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Sieper J
Rheumatology (Oxford); 2005 May; 44(5):670-6. PubMed ID: 15757965
[TBL] [Abstract][Full Text] [Related]
11. Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study.
Marzo-Ortega H; McGonagle D; Jarrett S; Haugeberg G; Hensor E; O'connor P; Tan AL; Conaghan PG; Greenstein A; Emery P
Ann Rheum Dis; 2005 Nov; 64(11):1568-75. PubMed ID: 15829577
[TBL] [Abstract][Full Text] [Related]
12. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis.
Maksymowych WP; Poole AR; Hiebert L; Webb A; Ionescu M; Lobanok T; King L; Davis JC
J Rheumatol; 2005 Oct; 32(10):1911-7. PubMed ID: 16206346
[TBL] [Abstract][Full Text] [Related]
13. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.
Rudwaleit M; Listing J; Brandt J; Braun J; Sieper J
Ann Rheum Dis; 2004 Jun; 63(6):665-70. PubMed ID: 15037444
[TBL] [Abstract][Full Text] [Related]
14. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study.
Braun J; Landewé R; Hermann KG; Han J; Yan S; Williamson P; van der Heijde D;
Arthritis Rheum; 2006 May; 54(5):1646-52. PubMed ID: 16646033
[TBL] [Abstract][Full Text] [Related]
15. Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: results from a randomized, placebo-controlled trial.
van der Heijde D; Han C; DeVlam K; Burmester G; van den Bosch F; Williamson P; Bala M; Han J; Braun J
Arthritis Rheum; 2006 Aug; 55(4):569-74. PubMed ID: 16874778
[TBL] [Abstract][Full Text] [Related]
16. Low-dose infliximab (3 mg/kg) significantly reduces spinal inflammation on magnetic resonance imaging in patients with ankylosing spondylitis: a randomized placebo-controlled study.
Maksymowych WP; Salonen D; Inman RD; Rahman P; Lambert RG;
J Rheumatol; 2010 Aug; 37(8):1728-34. PubMed ID: 20436073
[TBL] [Abstract][Full Text] [Related]
17. Cartilage biomarkers in ankylosing spondylitis: relationship to clinical variables and treatment response.
Kim TH; Stone M; Payne U; Zhang X; Ionescu M; Lobanok T; King L; Poole AR; Inman RD
Arthritis Rheum; 2005 Mar; 52(3):885-91. PubMed ID: 15751093
[TBL] [Abstract][Full Text] [Related]
18. Infliximab in severe active ankylosing spondylitis with spinal ankylosis.
Cheung PP; Tymms KE; Wilson BJ; Shadbolt B; Brook AS; Dorai Raj AK; Khoo KB
Intern Med J; 2008 Jun; 38(6):396-401. PubMed ID: 18336538
[TBL] [Abstract][Full Text] [Related]
19. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data.
Baraliakos X; Brandt J; Listing J; Haibel H; Sörensen H; Rudwaleit M; Sieper J; Braun J
Arthritis Rheum; 2005 Dec; 53(6):856-63. PubMed ID: 16342093
[TBL] [Abstract][Full Text] [Related]
20. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept.
Woo JH; Lee HJ; Sung IH; Kim TH
J Rheumatol; 2007 Aug; 34(8):1753-9. PubMed ID: 17610317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
